Tradestie Institutional Equity Comparison Engine

SDEV vs APUS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

APUS Overall Edge

APUS Captures Institutional Edge (2โ€“0 Pillars ยท 8โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Apimeds Pharmaceuticals US, Inc. (APUS) driven by superior Growth & Margin, Momentum & Technical. Fundamentally, SDEV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus APUS at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SDEV sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against APUS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SDEV N/M vs APUS N/M Fwd P/E
Growth & Margin Winner APUS
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner APUS
1Y -62.4% vs +7.2% ยท 52W Pos 0% vs 16%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
SDEV US Equity
SDEV
Institutional Equity
$0.71
-9.42% 1D
Market Cap N/A
1M Return -19.79%
1Y Return -62.42%
Forward P/E N/M
Unified AI Score
45.8 / 100 HOLD
Tech 43.0 Fund 46.0 Flow 50.0 Mom 50.0
APUS NYSE American
Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations
$2.05
-7.91% 1D
Market Cap $3.4M
1M Return -49.17%
1Y Return +7.18%
Forward P/E N/M
Unified AI Score
48.5 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SDEV -62.42% APUS +7.18% Spread: +19.04 pp (APUS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SDEV TTM Op. Margin: N/A APUS TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SDEV vs APUS. Trailing 12-month operating profitability (SDEV N/A vs APUS 0.0%) and valuation multiples (SDEV N/M vs APUS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SDEV (0) vs APUS (8)
Institutional Metric SDEV APUS Criterion Row Winner
Market Capitalization Scale N/A $3.4M Larger Scale APUS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth APUS
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin APUS
Net Profit Margin Profitability N/A 0.0% Higher Margin APUS
Return on Equity (ROE) Capital Efficiency N/A 0.0% Higher ROE APUS
52-Week Range Position Momentum 0% ($1โ€“$10) 16% ($1โ€“$10) Stronger Trend APUS
Beta / 30D Volatility Risk Regime 1.47ฮฒ ยท 154% Vol 2.97ฮฒ ยท 67% Vol Lower Realized Risk APUS
Unified Institutional Score Composite Signal 45.8 / 100 (HOLD) 48.5 / 100 (HOLD) Higher Composite APUS

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SDEV vs APUS Buy Guide
SDEV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live SDEV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
APUS UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live APUS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SDEV nor APUS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.